A longitudinal single-cell atlas to predict outcome and toxicity after BCMA-directed CAR T cell therapy in multiple myeloma

Michael Rade, David Fandrei, Markus Kreuz, Sabine Seiffert, Thomas Wiemers, Patrick Born, Luise Fischer, Heike Weidner, Lorenz Hofbauer, Ronny Baber, Song-Yau Wang, Enrica Bach, Sandra Hoffmann, Jonathan Scolnick, Mirco Friedrich, Farid Keramati, Peter Brazda, Zsolt Sebestyen, Jürgen Kuball, Klaus Metzeler, Marco Herling, Carmen Herling, Madlen Jentzsch, Georg-Nikolaus Franke, Andreas Boldt, Anja Grahnert, Maik Friedrich, Ulrike Köhl, Uwe Platzbecker, Vladan Vucinic, Kristin Reiche, Maximilian Merz
March 2025
PDF Cite

Abstract

This study presents a longitudinal single-cell multi-omics atlas of immune dynamics in multiple myeloma patients treated with BCMA-directed CAR T cells. Using data from 61 patients, it identifies immunological biomarkers linked to treatment efficacy and toxicity, providing insights into CAR-T expansion, B-cell recovery, tumor burden, and cytokine release syndrome. The atlas highlights CD4+CAR+ T cells as critical for durable response and reveals differential gene programs in responders versus non-responders, advancing personalized immunotherapy.

Type
Journal article
Publication
Research Square Preprint